For patients with IgG kappa multiple myeloma receiving an IgG kappa mAb (i.e., daratumumab), how important is it clinically to use an interference assay if they're in a VGPR to see if their M-spike might actually be 0?

For example, would you use a tool like the Hydrashift assay? Would this change your management?

Answer from: Medical Oncologist at Academic Institution

I always try to perform an assay to distinguish an IgG kappa monoclonal protein from the therapeutic antibody of interest. For daratumumab, the ‘hydra shift’ assay has been used for a while. Now, with Mass spectrometry available, it is the perfect way to assess very sensitively for a res...

Comments

Medical Oncologist at University of Michigan
I'd like to second the concept, "why do it unless ...

Please select the option that best describes you:

For patients with IgG kappa multiple myeloma receiving an IgG kappa mAb (i.e., daratumumab), how important is it clinically to use an interference assay if they're in a VGPR to see if their M-spike might actually be 0?

Related Questions